Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in brain excitatory neurons (100 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 35 | 0.85 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 4211
Sealed predictions
- CLSTN3 in dopamine neurons, braak-0.44 (p 0.234) → +0.03 (p 0.946)receipt 4218
Swarm cases
receipt 4218: CLSTN3 in dopamine neurons, braak
- power
- full sample -0.20 (p 0.429, n 18), 95% CI -0.61 to +0.30. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.28 (p 0.261, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.43 (p 0.074, n 18). could be the mix.
- skeptic
- leave-one-out range -0.33 to -0.09, sign flips 0; without severely affected donors -0.20 (p 0.429, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.59 (p 0.0096, n 18) vs -0.20 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CLSTN3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CLSTN3 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.35 p 0.214 (needs p < 4.7e-4)
Receipts
loading the receipts